164 related articles for article (PubMed ID: 34453496)
1. Comprehensive expressional analysis of chemosensitivity-related markers in large cell neuroendocrine carcinoma of the lung.
Ohtaki Y; Kaira K; Yajima T; Erkhem-Ochir B; Kawashima O; Kamiyoshihara M; Igai H; Onozato R; Ibe T; Kosaka T; Nakazawa S; Nagashima T; Oyama T; Shirabe K
Thorac Cancer; 2021 Oct; 12(20):2666-2679. PubMed ID: 34453496
[TBL] [Abstract][Full Text] [Related]
2. Clinical Significance of Various Drug-Sensitivity Markers in Patients with Surgically Resected Pulmonary Pleomorphic Carcinoma.
Imai H; Shimizu K; Kawashima O; Endoh H; Imaizumi K; Goto Y; Kamiyoshihara M; Sugano M; Yamamoto R; Tanaka S; Fujita A; Kogure Y; Seki Y; Mogi A; Oyama T; Minato K; Asao T; Kaira K
Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31653009
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Biomarkers for Personalized Treatment in Pulmonary Large Cell Neuroendocrine Carcinoma: A Comparative Analysis With Adenocarcinoma.
Makino T; Mikami T; Hata Y; Otsuka H; Koezuka S; Isobe K; Tochigi N; Shibuya K; Homma S; Iyoda A
Ann Thorac Surg; 2016 Nov; 102(5):1694-1701. PubMed ID: 27368130
[TBL] [Abstract][Full Text] [Related]
4. Analysis of 5-fluorouracil-related enzymes in pulmonary neuroendocrine carcinoma: differences in biological properties compared to epithelial carcinoma.
Nagasaki T; Tsuchiya T; Tagawa T; Honda S; Yamasaki N; Miyazaki T; Hidaka S; Hayashi T; Nagayasu T
Clin Lung Cancer; 2010 Nov; 11(6):412-22. PubMed ID: 21062732
[TBL] [Abstract][Full Text] [Related]
5. CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen.
Silvestris N; Simone G; Partipilo G; Scarpi E; Lorusso V; Brunetti AE; Maiello E; Paradiso A; Mangia A
Int J Mol Sci; 2014 Sep; 15(9):15767-77. PubMed ID: 25198900
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological significance of cancer stem-like cell markers in high-grade neuroendocrine carcinoma of the lung.
Morise M; Hishida T; Takahashi A; Yoshida J; Ohe Y; Nagai K; Ishii G
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2121-30. PubMed ID: 25963795
[TBL] [Abstract][Full Text] [Related]
7. Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study.
Zhang JT; Li Y; Yan LX; Zhu ZF; Dong XR; Chu Q; Wu L; Zhang HM; Xu CW; Lin G; Yu ZY; Hu J; Zhu B; Wang HJ; Yang F; Song ZB; Han ZB; Li MX; Lin J; Wu YL; Wang JL; Zhong WZ
Lung Cancer; 2020 Jan; 139():118-123. PubMed ID: 31775086
[TBL] [Abstract][Full Text] [Related]
8. Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.
Liu D; Nakashima N; Nakano J; Tarumi S; Matsuura N; Nakano T; Nii K; Tokunaga Y; Go T; Yokomise H
Anticancer Res; 2017 May; 37(5):2501-2507. PubMed ID: 28476819
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of topoisomerase-II expression in patients with advanced non-small cell lung cancer treated with amrubicin.
Sakurai R; Kaira K; Miura Y; Sunaga N; Saito R; Oyama T; Hisada T; Yamada M
Thorac Cancer; 2020 Feb; 11(2):426-435. PubMed ID: 31901017
[TBL] [Abstract][Full Text] [Related]
10. Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy.
Kostopoulos I; Karavasilis V; Karina M; Bobos M; Xiros N; Pentheroudakis G; Kafiri G; Papakostas P; Vrettou E; Fountzilas G
BMC Cancer; 2009 Sep; 9():339. PubMed ID: 19775480
[TBL] [Abstract][Full Text] [Related]
11. Prognostic effect of class III β-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors.
Miura Y; Kaira K; Sakurai R; Imai H; Tomizawa Y; Sunaga N; Minato K; Hisada T; Oyama T; Yamada M
Oncol Lett; 2017 Aug; 14(2):2369-2378. PubMed ID: 28789453
[TBL] [Abstract][Full Text] [Related]
12. Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma.
Shirasawa M; Yoshida T; Takayanagi D; Shiraishi K; Yagishita S; Sekine K; Kanda S; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Hamada A; Kohno T; Yamamoto N; Watanabe SI; Ohe Y; Motoi N
Clin Lung Cancer; 2021 Jul; 22(4):282-291.e6. PubMed ID: 33722498
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocytes in large cell neuroendocrine carcinoma of lung.
Ohtaki Y; Kaira K; Atsumi J; Nagashima T; Kawashima O; Ibe T; Kamiyoshihara M; Onozato R; Fujita A; Yazawa T; Sugano M; Iijima M; Nakazawa S; Obayashi K; Kosaka T; Yajima T; Kuwano H; Shirabe K; Mogi A; Shimizu K
Am J Transl Res; 2018; 10(10):3243-3253. PubMed ID: 30416665
[TBL] [Abstract][Full Text] [Related]
14. Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy.
Saji H; Tsuboi M; Matsubayashi J; Miyajima K; Shimada Y; Imai K; Kato Y; Usuda J; Kajiwara N; Uchida O; Ohira T; Hirano T; Mukai K; Kato H; Ikeda N
Anticancer Drugs; 2010 Jan; 21(1):89-93. PubMed ID: 19770636
[TBL] [Abstract][Full Text] [Related]
15. High expression of topoisomerase-II predicts favorable clinical outcomes in patients with relapsed small cell lung cancers receiving amrubicin.
Miura Y; Kaira K; Sakurai R; Sunaga N; Saito R; Hisada T; Yamada M
Lung Cancer; 2018 Jan; 115():42-48. PubMed ID: 29290260
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer.
Corsi DC; Ciaparrone M; Zannoni G; Mancini M; Cassano A; Specchia M; Pozzo C; Martini M; Barone C
Eur J Cancer; 2002 Mar; 38(4):527-34. PubMed ID: 11872345
[TBL] [Abstract][Full Text] [Related]
17. A clinicopathological study of peripheral, small-sized high-grade neuroendocrine tumours of the lung: differences between small-cell lung carcinoma and large-cell neuroendocrine carcinoma.
Isaka M; Nakagawa K; Ohde Y; Okumura T; Watanabe R; Ito I; Nakajima T; Kondo H
Eur J Cardiothorac Surg; 2012 Apr; 41(4):841-6. PubMed ID: 22219429
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic value of thymidylate synthase, topoisomerase-1 and Ki-67 in advanced colorectal cancer patients on irinotecan and fluorouracil treatment].
Xu JM; Zhu BD; Mangia A; Simone G; Montemurro S; Giuliani F; Maiello E; Colucci G; Paradiso A
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):312-5. PubMed ID: 15996331
[TBL] [Abstract][Full Text] [Related]
19. Expression of a molecular marker panel as a prognostic tool in gastric cancer patients treated postoperatively with docetaxel and irinotecan. A study of the Hellenic Cooperative Oncology Group.
Skarlos DV; Bai M; Goussia A; Samantas E; Galani E; Tsavdaridis D; Karina M; Papakostas P; Konstantara A; Fountzilas G
Anticancer Res; 2007; 27(4C):2973-83. PubMed ID: 17695481
[TBL] [Abstract][Full Text] [Related]
20. Expression of ERCC1, TYMS, RRM1, TUBB3, non-muscle myosin II, myoglobin and MyoD1 in lung adenocarcinoma pleural effusions predicts survival in patients receiving platinum-based chemotherapy.
Jiang H; Wang H; Wang S; Pei Z; Fu Z; Fang C; Wang J; Lu Q; Wang E; Li J
Mol Med Rep; 2015 May; 11(5):3523-32. PubMed ID: 25573098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
